Rani Therapeutics Holdings Inc [RANI] stock is trading at $1.44, up 5.11%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RANI shares have gain 3.60% over the last week, with a monthly amount drifted -5.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rani Therapeutics Holdings Inc [NASDAQ: RANI] stock has seen the most recent analyst activity on August 02, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $17. Previously, Maxim Group started tracking the stock with Buy rating on June 14, 2024, and set its price target to $15. On June 13, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $10 on the stock. UBS initiated its recommendation with a Buy and recommended $15 as its price target on October 11, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on July 27, 2022, and assigned it a price target of $22. In a note dated June 13, 2022, Wedbush initiated an Outperform rating and provided a target price of $28 on this stock.
Rani Therapeutics Holdings Inc [RANI] stock has fluctuated between $1.24 and $8.75 over the past year. Currently, Wall Street analysts expect the stock to reach $15.67 within the next 12 months. Rani Therapeutics Holdings Inc [NASDAQ: RANI] shares were valued at $1.44 at the most recent close of the market. An investor can expect a potential return of 988.19% based on the average RANI price forecast.
Analyzing the RANI fundamentals
Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -18.83%, Pretax Profit Margin comes in at -19.97%, and Net Profit Margin reading is -10.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -4.3 and Total Capital is -2.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of10.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3833 points at the first support level, and at 1.3267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4733, and for the 2nd resistance point, it is at 1.5067.
Ratios To Look Out For
For context, Rani Therapeutics Holdings Inc’s Current Ratio is 1.60. As well, the Quick Ratio is 1.60, while the Cash Ratio is 0.21.
Transactions by insiders
Recent insider trading involved McKinley Kate, Chief Business Officer, that happened on Dec 13 ’24 when 17960.0 shares were purchased. Chief Executive Officer, Imran Talat completed a deal on Dec 09 ’24 to buy 10296.0 shares. Meanwhile, 10% Owner South Cone Investments Limited sold 3.83 million shares on Oct 15 ’24.
